• Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
  

PubMed=10992426; DOI=10.1016/S0022-5347(05)67210-2
Patel B.J., Pantuck A.J., Zisman A., Tsui K.-H., Paik S.H., Caliliw R., Sheriff S., Wu L., deKernion J.B., Tso C.-L., Belldegrun A.S.
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
J. Urol. 164:1420-1425(2000)

PubMed=11038142
Tso C.-L., McBride W.H., Sun J.-R., Patel B.J., Tsui K.-H., Paik S.H., Gitlitz B., Caliliw R., van Ophoven A., Wu L., deKernion J.B., Belldegrun A.S.
Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Cancer J. Sci. Am. 6:220-233(2000)

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=15833837; DOI=10.1158/0008-5472.CAN-04-3218
Lin B.-Y., White J.T., Lu W., Xie T., Utleg A.G., Yan X.-W., Yi E.C., Shannon P., Khrebtukova I., Lange P.H., Goodlett D.R., Zhou D.-X., Vasicek T.J., Hood L.E.
Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.
Cancer Res. 65:3081-3091(2005)